PCV54 Can A Cvd Polypill Save Money In The ‘Real World'?  by Laba, T.L. et al.
A482  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
model was a hospital in the United States (US). Clinical data was obtained from US 
pivotal studies for the Medtronic stent system and the competing stent systems. The 
competition arm (Competition) was created by pooling the pivotal study data for the 
current stent systems manufactured by Gore, Endologix, and Cook. Cost data was 
obtained from the Premier database (2011-2012) and augmented with the published 
literature. All costs were adjusted to 2013 dollars. The model estimated the costs 
associated with the following utilization outcomes: procedure time, transfusion rate, 
intensive care unit (ICU) length of stay (LOS), and general ward LOS. The following 
adverse events were considered: myocardial infarction, respiratory failure, acute 
renal failure, stroke/TIA, and second endovascular procedure within 12 months of 
the initial procedure. Sensitivity analysis was performed to assess the impact of 
imputed data, and one-way sensitivity analysis was performed for each parameter.  
Results: The expected costs for a hospital related to the above utilization and 
adverse event were $8,463 for Medtronic’s stent graft system and $11,380 for the 
Competition. Fifty-six percent of the $2,917 difference was attributable to improved 
utilization associated with Medtronic’s stent graft compared to the Competition. 
Adverse events and secondary endovascular procedures accounted for 25% and 19% 
of the difference, respectively. These results were robust to alternative sensitivity 
analyses. ConClusions: This analysis suggested that Medtronic’s current stent 
graft is associated with cost savings compared to Competition for the above param-
eters. Future research is necessary to examine if these results are maintained based 
upon a head-to-head clinical study of EVAR stent systems.
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objeCtives: ADVANCEIII trial showed that a long detection programming reduces 
all delivered therapies as well as inappropriate shocks in patients implanted with 
implantable cardioverter defibrillator (ICD). The purpose of this Advance III sec-
ondary analysis was to assess the impact of long detection on hospitalizations (H), 
length of stay (LOS) and associated costs for the health care system. Methods: 
1902 patients enrolled in the ADVANCEIII Trial: 948 patients randomized to long 
detection (NID 30/40) and 954 to short setting (NID 18/24). All hospitalizations 
were reviewed and classified according to ICD9CM codes and, consequently, to the 
corresponding Diagnosis-Related Groups (DRGs). Costs correspond to the specific 
public tariffs for the DRGs applied. The prospective was of a single-payer agent 
(Italian Ministry of Health). Results: Over a median period of 12 months, rates 
of overall and cardiovascular hospitalizations (CV) were lower in the long detec-
tion group (43.8*100 pts/years (39.6-48.4) vs 52.3*100 pts/years (47.7-57.3), IRR: 0.84 
(0.73-0.96) p= 0.005,32.7*100 pts/years (29.1-36.7) vs 40.3*100 pts/years (36.2-44.6), 
IRR (95% CI): 0.81 (0.69-0.95) p= 0.004 respectively). Patients programmed with a 
long detection had shorter LOS (overall H: 407days (394-421) vs 470 days (456-484), 
IRR: 0.87 (0.83-0.91) p< 0.001; CV: 298 days (287-309) vs 368 days (356-381), IRR: 0.81 
(0.77-0.85) p< 0.001) and lower mean hospital cost per patient-year compared with 
patients with nominal programming (overall H: 1.311 € (1.309 € - 1.314 € ) versus 
1.528€ (1.525€ - 1.530€ ) IRR: 0.86 (0.86-0.86) p< 0.001; CV: 1.100 € (1.098 € - 1.103 € ) 
versus 1.339 € (1.337 € - 1.342 € ) IRR: 0.86 (0.86-0.86) p< 0.001). ConClusions: 
A long detection window was associated with a reduction in hospitalization rates, 
total length of stay and cost per patients both for all-causes and cardiovascular 
related events.
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objeCtives: The rising cost of treatment of peripheral arterial disease and the 
growing incidence of this disease led to economic analysis of arterial disease. With 
the increasing price of modern instrumentation, it is appropriate to evaluate not 
only clinical efficiency, but also intervention economics. This study aims to create a 
recommendation for choosing the most effective treatment based on both economic 
data and clinical outputs of the disabled superficial femoral artery. Methods: The 
methods chosen were reviewed from clinical outputs for treatment effectiveness, 
multiple-criteria decision-making for the synthesis of treatment effects, analysis of 
costs at the selected interventions and cost-effectiveness analysis. Results: The 
four clinical outputs used in the study as a criterion by the research of the clinical 
studies were primary patency, technical success, patient survival and limb salvage at 
the year of operation. The weights of each criterion, and the preferences of the inter-
ventions were counted. The sequence of interventions was set by the AHP method: 
PTA (35.6%), PTA/S (33.9%) and bypass (30.6%) and method of weighted sum: PTA/S 
(56%), bypass (55%) and PTA (42%). From the view of both health insurance payer and 
health care provider, where the direct medical expenditures were included, the order 
of intervention was the same: PTA, bypass and PTA/S. The cost-effectiveness was 
calculated for both, and the PTA intervention achieved the best results. Incremental 
expenditures by unit of effect was calculated for each effect: ICER or the domination 
of one intervention over another was set. Ratio of the ICER was generally higher for 
PTA/S compared to bypass. In the sensitive analysis was determined the influence of 
in Acute Kidney Injury (AKI) rate of about 40%. Aim of this study is to perform an 
economic evaluation of GDP strategy with respect to TP in UK and US. Methods: 
A Discrete Event Simulation model was developed to compare TP and GDP strategy 
in patients undergoing CPB. The patient’s pathways from operation to discharging 
from hospital was simulated: AKI incidence, in-hospital mortality, hospital length 
of stay, transfusions were correlated to probability to achieve high DO2 target using 
published correlations. National perspective was adopted to calculate costs asso-
ciated to each event while GDP strategy was exploited considering card and data 
management system (DMS) cost per patient. Results: GDP strategy saved more 
than 3 days in hospital and 11% of AKI episodes. The cost-saving is 2,821 £ in UK 
and 3,206 $ in US; the cost of card and DMS (79 £ in UK, 110 $ in US) is completely 
offset by savings in hospital stay that result the main driver in cost (2,886 £ in UK, 
3,222 $ in US). Deterministic sensitivity analysis shows that the total savings are 
mainly influenced by hospital LOS, cost per day both in ICU and in ward, and nadir 
haematocrit during CPB. ConClusions: GDP seems to improve significantly the 
main outcomes related to CPB surgery, when compared to TP techniques. Additional 
costs due to perform GDP strategy have no impact on the total cost since completely 
offset by the savings in hospital cost.
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objeCtives: The use of polypills in the prevention of cardiovascular disease is 
mooted to reduce costs compared with current practice, yet there is very little 
prospectively-collected data to support this claim. The present study compares 
the ‘real-world’ costs of a polypill strategy against usual care among Australians 
with established cardiovascular disease or at high estimated cardiovascular 
risk. Methods: A ‘within trial’ cost analysis from the Australian health system 
perspective of polypill-based care versus usual care with separate medications 
was conducted using data from the pragmatic randomised controlled trial Kanyini 
Guidelines Adherence to Polypill (Kanyini GAP) and linked health service and medi-
cation claims data. The primary outcome, estimated with generalised linear models, 
was mean health service and pharmaceutical expenditure, per patient per year. 
All costs during the trial, conducted from 2008-2012, were inflated to $AUD 2012 
prices. Results: A statistically significantly lower mean pharmaceutical expendi-
ture of $989 (95%CI 648 to 1331) per patient per year in the polypill arm compared 
to usual care (P< 0.001, adjusted, excluding polypill cost). No significant differences 
were observed in annual non-hospital health service expenditure ($40, 95%CI -202 to 
281 per patient). ConClusions: This study provides evidence that a cardiovascular 
disease polypill strategy has the potential to produce significant cost-savings to 
health systems. At an estimated reimbursement cost of $1 per day for the polypill, 
these savings would have amounted to over $600 per patient per year. Cost-savings 
would accrue to patients also, given fewer prescription charges. Linking health 
service and medication claims data with data from a pragmatic randomised con-
trolled trial has provided an avenue to assess the real-world cost implications of 
introducing this new technology into clinical practice.
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objeCtives: There is a growing prevalence of diabetes mellitus (DM) among chronic 
diseases in the world. Currently there are over 135 million people with diabetes 
worldwide with estimates reaching 300 million in 2025. Developing countries con-
centrate two thirds of these patients and it is known that the economic burden of 
chronic diseases generate high costs for the health system and social welfare as 
a function of mortality and premature disability. The objective of the study was to 
investigate the impact on hospital costs of treating a patient with ischemic heart 
disease and DM, compared with cardiac patients without DM, in a cardiology hospi-
tal of high complexity Ministry of Health in Brazil. Methods: observational study 
of historical cohort of 421 diabetic heart disease (CD) and non diabetic (CND), from 
January 2009 to March 2010 in cardiology hospital of high complexity of the Unified 
Health System (SUS) in Brazil. Were only covered the direct medical costs of hos-
pitalizations. The costs of the study population (CD and CND) were grouped into 
surgery, and clinical treatment obtained by two different approaches (top-down and 
bottom-up estimates), and subsequently analyzed and compared using R software 
version 3.0. Results: No differences between groups were observed. Cost of sur-
gery: CND = U. S. $ 2937.55 and U. S. $ 3024.51 = CD (p = 0.319). Medical Treatment: 
CND = U. S. $ 685.09 and U. S. $ 304.11 = CD (p = 0.218). Values are expressed as 
medians. ConClusions: studies analyzing these conditions separately describe 
high expenses resulting from the treatment of diabetes and cardiovascular disease. 
We can infer from the results of this study that the diabetic patient cardiac does not 
generate a significant financial impact for a cardiology hospital of high complexity.
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objeCtives: To perform a cost comparison analysis of Medtronic’s current stent 
graft system compared to currently competing stent graft systems for endovas-
cular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA). Methods: 
A simulation model was constructed using Microsoft Excel. The perspective of the 
